Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Mesoblast Limited (MESO) vs Spotify Technology (SPOT) Price & Performance

Mesoblast LimitedTrade
Spotify TechnologyTrade

Price performance (Past 24H)

Key statistics

Mesoblast Limited vs Spotify Technology — how do they compare? Mesoblast Limited trades at $16.68 (market cap $2.16B), while Spotify Technology trades at $501.27 (market cap $105.22B). The key difference: Spotify Technology is far larger — about 48.7× Mesoblast Limited's market cap, and Mesoblast Limited is trading nearer its 52-week high, Spotify Technology nearer its low. Which is the better fit depends on your goals.

MESOSPOT
Market Cap
$2.16B$105.22B
Sector
TechnologyMedia
52-Week High
$20.96$738.53
52-Week Low
$12.88$412.75
Enterprise Value
$2.17B$94.91B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Mesoblast Limited

MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.

Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.

Spotify Technology

Spotify (SPOT) trades at $488.14, up 2.75% with mixed technical signals showing neutral overall momentum. The company demonstrates strong fundamental performance with Q2 2026 revenue growth of 14% year-over-year and record gross margins of 33.4%, though earnings missed expectations due to increased marketing and AI costs. Premium subscribers surpassed 300 million for the first time, supporting the long-term growth narrative.

Wall Street maintains a bullish outlook with 61.5% buy ratings and a $598.20 consensus price target representing 22.5% upside potential. Key risks include execution on AI investments, competitive pressure in streaming, and margin sustainability. The stock presents growth opportunity if monetization initiatives succeed.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO

About Spotify Technology

Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.

Read more on SPOT